RNA Atrium Therapeutics, Inc.

Fundamentals / CIK 0002093101 / USD

Atrium Therapeutics, Inc. reported $264.0M in total assets through September 30, 2026 from SEC EDGAR filings.

Audited annual (10-K / 20-F) and quarterly (10-Q) statements parsed directly from SEC EDGAR CompanyFacts. Open RNA in the Convexity terminal for live prices, valuation multiples, transcripts, and insider flow.

Financial statements and ratios

Reported in USD. Per-share figures and share counts are adjusted for stock splits from SEC filings.

Income Statement (Annual) · Reported in USD · Newest filing period first.

No annual income statement rows are available in SEC EDGAR CompanyFacts for RNA.

Income Statement (Quarterly) · Reported in USD · Newest filing period first.

Income Statement 2026-09-30 2026-06-30 2026-03-31 2025-09-30 2025-06-30 2025-03-31
Revenue $15.32M $3.00M $19.64M $12.34M $3.85M $1.57M
Research & Development $13.80M $15.34M $16.66M $9.75M $13.29M $6.94M
Total Operating Expenses $21.95M $25.62M $36.91M $12.55M $16.71M $9.03M
Operating Income -$6.63M -$22.62M -$17.28M -$213K -$12.86M -$7.45M
EBITDA -$6.28M -$22.27M -$17.13M -$144K -$12.79M -$7.40M
Interest Income $2.19M $2.10M -- $0 $0 --
Income Before Tax -$4.27M -- -- -$213K -- --
Income Tax Expense $0 -- -- -$176K -- --
Net Income -$4.27M -$20.19M -$16.63M -$37K -$12.88M -$7.45M
Basic EPS -$0.25 -$1.18 -$0.97 $0.00 -$0.75 -$0.44
Diluted EPS -$0.25 -$1.18 -$0.97 $0.00 -$0.75 -$0.44
Basic Shares Outstanding 17.0M 17.1M 17.1M 17.1M 17.1M 17.1M
Diluted Shares Outstanding 17.0M 17.1M 17.1M 17.1M 17.1M 17.1M

Balance Sheet (Annual) · Reported in USD · Newest filing period first.

No annual balance sheet rows are available in SEC EDGAR CompanyFacts for RNA.

Balance Sheet (Quarterly) · Reported in USD · Newest filing period first.

Balance Sheet 2026-09-30 2026-06-30 2026-03-31 2025-12-31
Cash & Cash Equivalents $44.56M $72.33M $267.8M $0
Short-Term Investments $187.5M $191.6M -- $0
Cash & Short-Term Investments $232.1M $263.9M $267.8M $0
Other Current Assets $2.13M $6.33M $138K $1.31M
Total Current Assets $258.1M $275.1M $285.6M $2.85M
Property, Plant & Equipment, Net $4.19M $4.07M $4.34M $2.72M
Other Non-Current Assets $1.12M -- -- $0
Total Non-Current Assets $5.93M $5.46M $6.79M $5.51M
Total Assets $264.0M $280.5M $292.4M $8.35M
Accounts Payable $782K $3.51M $807K $4.40M
Deferred Revenue (Current) $9.45M $9.04M $9.34M $21.64M
Total Current Liabilities $24.66M $31.51M $21.91M $41.80M
Deferred Revenue (Non-Current) $32.92M $33.65M $36.35M $28.69M
Other Non-Current Liabilities $1.38M $775K $0 $574K
Total Non-Current Liabilities $34.30M $34.43M $36.35M $29.27M
Total Liabilities $58.97M $65.94M $58.26M $71.07M
Total Debt (incl. Leases) $679K $1.68M $2.68M $3.67M
Common Stock $16K $16K $16K $0
Retained Earnings -$12.32M -$8.06M $12.13M $0
Accumulated Other Comp. Income -$347K -$235K -- $0
Total Stockholders' Equity $205.0M $214.6M $234.1M -$62.71M
Total Equity $205.0M $214.6M $234.1M -$62.71M

Cash Flow Statement (Annual) · Reported in USD · Newest filing period first.

No annual cash flow statement rows are available in SEC EDGAR CompanyFacts for RNA.

Cash Flow Statement (Quarterly) · Reported in USD · Newest filing period first.

Cash Flow Statement 2026-09-30 2026-06-30 2026-03-31 2025-09-30 2025-06-30 2025-03-31
Net Income -$4.27M -$20.19M -$16.63M -$37K -$12.88M -$7.45M
Depreciation & Amortization $352K $343K $151K $69K $79K $53K
Stock-Based Compensation $1.12M $893K $12.21M $1.22M $1.70M $1.21M
Change in Receivables -- -- -$15.00M -- -- $0
Change in Payables -$2.73M $2.71M -$3.59M $140K -$258K $37K
Operating Cash Flow -$25.37M -$3.93M -$31.14M $1.13M -$11.91M -$11.10M
Capital Expenditure -$415K -$36K -$2.10M -$300K -$266K $0
Free Cash Flow -$25.78M -$3.96M -$33.24M $833K -$12.17M -$11.10M
Investing Cash Flow $3.90M -$191.6M -$2.10M -$300K -$266K $0
Financing Cash Flow -$6.30M $0 $301.5M -$833K $12.17M $11.10M
Net Change in Cash -$27.77M -$195.5M $268.3M $0 $0 $0

Margins, returns, leverage, liquidity, and year-over-year growth computed directly from SEC EDGAR statement levels. Multi-year figures show cumulative per-share growth.

No annual ratios & growth rows are available in SEC EDGAR CompanyFacts for RNA.

Quarterly margins, ROE, and ROA use trailing-twelve-month (TTM) flows summed across four contiguous quarters. Growth rates are true year-over-year comparisons against the same quarter a year earlier.

Ratios & Growth 2026-09-30 2026-06-30 2026-03-31 2025-09-30 2025-06-30 2025-03-31
Current Ratio 10.46x 8.73x 13.04x -- -- --
Quick Ratio 9.41x 8.38x 12.23x -- -- --
Debt to Equity 0.00x 0.01x 0.01x -- -- --
Revenue Growth (YoY) +24.2% -21.9% +1148.3% -- -- --
Operating Cash Flow Growth (YoY) -2339.0% -- -- -- -- --
Free Cash Flow Growth (YoY) -3195.2% -- -- -- -- --
Source: SEC EDGAR CompanyFacts (CIK 0002093101) · from March 31, 2025 Data through September 30, 2026 · synced Nov 20, 2026, 05:47 UTC · Open in terminal